

# NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

## HEALTH TECHNOLOGY APPRAISAL PROGRAMME

### Equality impact assessment – Guidance development

#### STA

### Caplacizumab with plasma exchange and immunosuppression for treating acquired thrombotic thrombocytopenic purpura [ID1185]

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

#### Consultation

1. Have the potential equality issues identified during the scoping process been addressed by the committee, and, if so, how?

During the scoping process consultees noted that people of certain religions, such as Jehovah's Witness, are unable to accept donor blood products. While caplacizumab is expected to be used as an adjunct to plasma exchange therapy, attendees at the workshop suggested it may be used on its own for these patients. The marketing authorisation for caplacizumab states that it is used with plasma exchange therapy. The Appraisal Committee had not been presented with any data for, and did not appraise, use of caplacizumab without plasma exchange which is outside of its marketing authorisation.

2. Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the committee addressed these?

The higher incidence of acquired TTP in women and people of African Caribbean family origin and the higher risk of acquired TTP in people with HIV was noted again. These were not considered to be equality issues

because it was considered unlikely that any recommendation would present barriers or limit access to these groups. Issues related to differences in prevalence or incidence of a disease cannot be addressed in a technology appraisal.

3. Have any other potential equality issues been identified by the committee, and, if so, how has the committee addressed these?

No

4. Do the preliminary recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

No

5. Is there potential for the preliminary recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

No

6. Are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality?

No

7. Have the committee's considerations of equality issues been described in the appraisal consultation document, and, if so, where?

No

**Approved by Associate Director (name):** Nicole Elliott

**Date:** 05/06/20

## Final appraisal determination

(when an ACD issued)

1. Have any additional potential equality issues been raised during the consultation, and, if so, how has the committee addressed these?

A consultee raised that it considered that the committee did not have the experience to review a technology designed for such a rare condition and reiterated the higher prevalence of acquired TTP in people of African-Caribbean family origin.

2. If the recommendations have changed after consultation, are there any recommendations that make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

The recommendations changed after consultation to recommend caplacizumab for acquired TTP. The marketing authorisation for caplacizumab was extended over the course of the appraisal to include people of 12 years and older as well as adults and the recommendations are for the full population covered by the marketing authorisation.

3. If the recommendations have changed after consultation, is there potential for the recommendations to have an adverse impact on

Technology appraisals: Guidance development

Equality impact assessment for the single technology appraisal of caplacizumab with plasma exchange and immunosuppression for treating acquired thrombotic thrombocytopenic purpura [ID1185]

3 of 5

Issue date: December 2020

people with disabilities because of something that is a consequence of the disability?

No

4. If the recommendations have changed after consultation, are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 2 and 3, or otherwise fulfil NICE's obligations to promote equality?

No

5. Have the committee's considerations of equality issues been described in the final appraisal determination, and, if so, where?

No, because the issues raised as potential equality issues by stakeholders were not considered to be equality issues. Furthermore the positive recommendation for caplacizumab was for the full population covered by its marketing authorisation.

**Approved by Associate Director (name):** Nicole Elliott

**Date:** 04/11/20

